Gynius AB, a Leading Swedish MedTech and e-Health company, has been included in a recently published study by WHO – The World Health Organization, screening women for Cervical Cancer

Human Papilloma Virus (HPV) testing and Visual Inspection with Acetic acid are the main screening methods used in low- and middle resource settings and screen positive women are recommended by the WHO to undergo further examination and direct treatment.

However, these screenings methods are not accurate enough as some results are false-positives. The consequence is; overtreatment leading to increased costs, complications as a result of the treatment and unnecessary referrals and causing healthy women with psychological distress.

In high resource settings, any cervical screen positive woman is referred for a colposcopy, where the woman’s cervix is viewed under a special microscope (Colposcope) and having a biopsy taken from abnormal areas. Until now, colposcopy have been difficult to implement in low and middle resource settings as traditional Colposcope’s are expensive, large, bulky and require access to electricity.

A team of researchers led by Dr. Partha Basu initiated a study to independently evaluate the accuracy of the GynocularTM, a Swedish innovation by Gynius AB, in detecting high grade pre-cancerous lesions of the cervix and to develop an algorithm for clinical management of VIA or HPV positive women.

Dr. Partha Basu and his team represents the Screening Group, Early detection and Prevention Section at the International Agency for Research on Cancer (IARC) within the WHO in France and the Chittaranjan National Cancer Institute in Kolkata, West Bengal, India,

The most important findings of the study were that the GynocularTM can successfully be used to triage screen-positive women, and correctly diagnose women with pre-cancerous lesions on-site. These women can be treated immediately, efficiently and safe, reducing both costs and human suffering.

The research team found the GynocularTM has high sensitivity and specificity to detect high-grade pre-cancerous lesions both in VIA positive and HPV positive women and that the accuracy is comparable to that of conventional colposcopy. The use of the GynocularTM reduced overtreatment with 70 percent and the researchers concluded that the GynocularTM show great promise as a triaging tool of VIA or HPV positive women.

“The results of the study deliver fantastic results, not at least for women in developing countries as we now can see how large-scale screenings can be executed without increasing the number of false-positive results. The results from the WHO researchers prove and validates our concept and the strength of our technology.” Said Dr. Elisabeth Wikström Shemer, MD, PhD, Senior Consultant of Obstetrics and Gynecology, Cevita Care St: Göran’s Hospital and Medical Director at Gynius AB “I am proud that our products show such high quality in Cervical screening diagnostics. The study shows how our products can bring the same level of diagnostics virtually anywhere, even to women in the most underdeveloped parts of the world.”

The Software developed by Gynius allows devices such as Android and iPhone into powerful tools for medical documentation and examination. The Software allows doctors, gynecologists, forensic nurses, scientists and other health workers to gather more accurately information from patients anywhere in the world using the secure and user friendly cloud-based software together with the GynocularTM.

To learn more about the GynocularTM and the cloud-based software and APP Technology please visit:

http://www.gynius.se/the-gynocular/

http://www.gynius.se/software/